comprehensive -WSS

comprehensive

author：hotspot 2025-10-01 04:13:03 - browse：5

ESMO signage in Madrid. — At ESMO 2023, antibody-drug conjugates were featured prominently. Andrew Joseph/STAT

MADRID — If you had to pinpoint one subject that stood out at this year’s European Society for Medical Oncology meeting, a massive conference with thousands of people from 140-some countries and 2,500 studies presented, it would be a burgeoning type of cancer treatment called antibody-drug conjugates.

The conference opened to the news that Merck had signed one of the biggest licensing deals in industry history — worth up to $22 billion — to partner on three of the compounds from ADC specialist Daiichi Sankyo. GSK followed up with an ADC licensing announcement of its own (if a much smaller one). Multiple ADC studies were presented at the meeting’s top sessions. ADCs were, in short, the belle of the cancer research ball.

The thing is, ADCs are actually quite an old approach.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： NIH trials fail to test meaningful long Covid therapies, experts say

Wikipedia

focus

WSS

South Korea throws huge K

Trump used to be more articulate. What could explain the change?

What to know about Virgin Galactic's 1st mission taking paying customers to space

Friends ask where James Watson's attitudes about race came from

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

explore

comprehensive

hotspot

Activists slam private health insurers over coverage restrictions

Slovenia has suffered its worst

How to save PrEP access — and even expand it

South Korea throws huge K

Cancer drug shortages should be causing more outrage

Feed a cold, starve a fever? Here’s what science says

Drug repurposing or repositioning? The language matters

Flash flood warnings continue for parts of Missouri, Illinois

Walensky prepares to leave CDC — and Congress — behind

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

leisure time

Wegovy’s successful heart trial raises vital question about weight loss

Maui's cultural, historic landmarks damaged in the devastating wildfires

Judge in Trump's classified documents case questions use of out

Wegovy trial has doctors encouraged over new possibilities

Why failed clinical trials don’t always spell doom for a new drug

How to use technology to prevent future drug shortages

Wikipedia

focus

focus

focus